<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00770835</url>
  </required_header>
  <id_info>
    <org_study_id>IT-PIO-109</org_study_id>
    <secondary_id>2007-003077-44</secondary_id>
    <secondary_id>U1111-1114-3045</secondary_id>
    <nct_id>NCT00770835</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.</brief_title>
  <acronym>SPLENDOR</acronym>
  <official_title>Effects of Pioglitazone on Endothelial Progenitor Cells in Type 2 Diabetic Patients With Vascular Complications - The SPLENDOR Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of pioglitazone compared to&#xD;
      glibenclamide, once daily (QD), taken together with metformin and lifestyle modification in&#xD;
      type 2 diabetic subjects with cardiovascular disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes is one of the most common chronic diseases worldwide, affecting nearly 200 million&#xD;
      people, almost all suffering from Type 2 Diabetes. It is the fourth leading cause of death in&#xD;
      developed countries due to the negative impact of the disease on the cardiovascular system.&#xD;
      Treatment, aimed to the reduction of this intrinsic cardiovascular risk, is based on tight&#xD;
      control of glucose and all coexisting metabolic abnormalities as well as of biomarkers of&#xD;
      inflammation and atherogenesis.&#xD;
&#xD;
      Macrovascular complications account for the vast majority of morbidity and mortality in&#xD;
      diabetic patients, and there is growing evidence that pathophysiologic mechanisms other than&#xD;
      hyperglycemia are responsible. The condition of the vascular endothelium in particular has&#xD;
      been shown to effect the health and disease of the cardiovascular system.&#xD;
&#xD;
      The number and function of endothelial progenitor cells correlate inversely with&#xD;
      cardiovascular risk factors and may be a surrogate biologic marker for vascular function and&#xD;
      cumulative cardiovascular risk.&#xD;
&#xD;
      Pioglitazone is an orally active thiazolidinedione derivative. It is a ligand for peroxisome&#xD;
      proliferator-activated receptor-gamma activation that alters transcription of various genes&#xD;
      regulating carbohydrate and lipid metabolism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase from Baseline in the number of Endothelial Progenitor Cells (CD34+KDR+).</measure>
    <time_frame>Baseline and Final Visit.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Circulating Progenitor Cells Integrated Markers of cardiovascular risk (CD34+).</measure>
    <time_frame>Baseline and Weeks 12 and 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Flow Mediated Dilation Integrated Markers of cardiovascular risk.</measure>
    <time_frame>Baseline and Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modulation of Endothelial Progenitor Cell recruitment (vascular endothelial growth factor, erythropoietin and stromal cell-derived factor-1).</measure>
    <time_frame>Weeks: 4, 12 and 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of Glucose Control (glycosylated hemoglobin and fasting plasma glucose).</measure>
    <time_frame>Weeks: 4, 12 and 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of Lipid Parameters (total lipids, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein B and apolipoprotein A1).</measure>
    <time_frame>Weeks: 4, 12 and 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in lipid parameters (free fatty acids and oxidized low-density lipoprotein).</measure>
    <time_frame>Baseline and Weeks 12 and 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in insulin sensitivity (insulin indexes by 2 hour oral glucose tolerance test with glucose, insulin and C-peptide estimation).</measure>
    <time_frame>Baseline and Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Inflammation Markers (high-sensitivity C-reactive protein, IL-6, vascular adhesion molecules (E-selectin, vascular cell adhesion molecule-1), monocyte chemotactic protein-1 and tumor necrosis factor-alpha).</measure>
    <time_frame>Baseline and Weeks 12 and 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Adipokines (adiponectin).</measure>
    <time_frame>Baseline and Weeks 12 and 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Oxidative Stress (maleic dialdehyde, ferric reducing antioxidant power and lipid hydroperoxide.</measure>
    <time_frame>Baseline and Weeks 12 and 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary albumin excretion.</measure>
    <time_frame>Weeks: 12 and 24.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Pioglitazone and Metformin QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(along with lifestyle modification)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glibenclamide and Metformin QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(along with lifestyle modification)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone and Metformin</intervention_name>
    <description>Pioglitazone 30 mg, tablets, orally, once daily, metformin stable dose and lifestyle modification for up to 24 weeks.</description>
    <arm_group_label>Pioglitazone and Metformin QD</arm_group_label>
    <other_name>ACTOSÂ®</other_name>
    <other_name>AD-4833</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glibenclamide and Metformin</intervention_name>
    <description>Glibenclamide 10 mg, tablets, orally, once daily and metformin stable dose and lifestyle modification for up to 24 weeks.</description>
    <arm_group_label>Glibenclamide and Metformin QD</arm_group_label>
    <other_name>Diabeta</other_name>
    <other_name>Glynase</other_name>
    <other_name>Micronase</other_name>
    <other_name>Daonil</other_name>
    <other_name>Semi-Daonil</other_name>
    <other_name>Euglucon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females must be non-pregnant, non-lactating and post-menopausal.&#xD;
&#xD;
          -  A glycosylated hemoglobin level greater than 7.5% and less than 10%.&#xD;
&#xD;
          -  Has an age of onset of Type 2 Diabetes greater than 35 years of age.&#xD;
&#xD;
          -  Is on metformin monotherapy up to the maximum tolerated daily dose.&#xD;
&#xD;
          -  Has a normal or only slightly impaired renal function (a modification of diet in renal&#xD;
             disease estimated glomerular filtration rate greater than 60 ml/min/1.73m2.&#xD;
&#xD;
          -  Antihypertensives, statins and any other hypolipidemic medications have been initiated&#xD;
             at least three months prior to enrollment; no dose modifications are allowed during&#xD;
             the study.&#xD;
&#xD;
          -  Has one or more cardiovascular comorbidities as follows:&#xD;
&#xD;
               -  stable angina pectoris&#xD;
&#xD;
               -  previous (greater than three months) transient ischemic attack, cerebrovascular&#xD;
                  accident or carotid atherosclerosis as assessed by bilateral carotid artery&#xD;
                  ultrasonography&#xD;
&#xD;
               -  peripheral vascular complications documented by a history of claudication or rest&#xD;
                  pain, ultrasonography or angiography.&#xD;
&#xD;
          -  and/or two or more of the following major cardiovascular risk factors:&#xD;
&#xD;
               -  hypertension (blood pressure &gt;130/80 mmHg or treatment)&#xD;
&#xD;
               -  dyslipidemia (low-density lipoprotein-cholesterol &gt;100 mg/dl or treatment and/or&#xD;
                  high-density lipoprotein-cholesterol &lt;40 mg/dl in men and &lt;45 mg/dl in women or&#xD;
                  treatment)&#xD;
&#xD;
               -  smoking (&gt;10 cigarettes/day)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has Type 1 Diabetes.&#xD;
&#xD;
          -  Is on insulin therapy.&#xD;
&#xD;
          -  Is severely obese defined as a body mass index greater than or equal to 40mg/m2&#xD;
&#xD;
          -  Has diabetic retinopathy.&#xD;
&#xD;
          -  Has evidence of hepatic dysfunction including liver transaminase greater than three&#xD;
             times the upper limit of normal.&#xD;
&#xD;
          -  Is unable to remain on a stable dose of the following class of medications 30 days&#xD;
             prior to randomization and throughout the six months of the study:&#xD;
&#xD;
               -  antihypertensives&#xD;
&#xD;
               -  statins&#xD;
&#xD;
               -  other hypolipidemic and antiplatelet drugs&#xD;
&#xD;
          -  Has a history of alcohol or other drug abuse.&#xD;
&#xD;
          -  Has had a new diagnosis of cancer or recurrent cancer within five years of screening.&#xD;
&#xD;
          -  Has a need for chronic (greater than two weeks) immunosuppressive therapy.&#xD;
&#xD;
          -  Has had heart failure based on the New York Heart Association Functional Class I&#xD;
             through IV.&#xD;
&#xD;
          -  Is required to take or intends to continue taking any disallowed medication, any&#xD;
             prescription medication, herbal treatment or over-the counter medication that may&#xD;
             interfere with evaluation of the study medication, including:&#xD;
&#xD;
               -  Other antidiabetic drugs (except metformin)&#xD;
&#xD;
               -  Fibrates&#xD;
&#xD;
               -  Rifampicin&#xD;
&#xD;
               -  Glibenclamide interacting drugs, including nonsteroidal anti-inflammatory agents&#xD;
&#xD;
               -  Other drugs that are highly protein bound, including:&#xD;
&#xD;
                    -  sulphonamides&#xD;
&#xD;
                    -  chloramphenicol&#xD;
&#xD;
                    -  probenecid&#xD;
&#xD;
                    -  monoamine oxidase inhibitors&#xD;
&#xD;
                    -  fluoroquinolones antibiotics&#xD;
&#xD;
                    -  oral miconazole&#xD;
&#xD;
          -  Has participated in another clinical study within the past three months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://general.takedapharm.com/content/file/pi.pdf?applicationcode=ab2d7112-8eb3-465a-8fda-35018a9eafb0&amp;fileTypeCode=ACTOSPI</url>
    <description>ACTOSÂ® Package Insert</description>
  </link>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>October 8, 2008</study_first_submitted>
  <study_first_submitted_qc>October 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2008</study_first_posted>
  <last_update_submitted>July 11, 2011</last_update_submitted>
  <last_update_submitted_qc>July 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Medical Director</name_title>
    <organization>Takeda Italia Farmaceutici S.p.A.</organization>
  </responsible_party>
  <keyword>Glucose Metabolism Disorder</keyword>
  <keyword>Dysmetabolic Syndrome</keyword>
  <keyword>Type II Diabetes</keyword>
  <keyword>Diabetes Mellitus, Lipoatrophic</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

